Hemorrhagic Transformation in Noncardioembolic Acute Ischemic Stroke: MRI Analysis From PACIFIC-STROKE

Author:

Chen Chih-Hao12ORCID,Shoamanesh Ashkan3ORCID,Colorado Pablo4ORCID,Saad Feryal1ORCID,Lemmens Robin5ORCID,De Marchis Gian Marco67ORCID,Caso Valeria8ORCID,Xu Lizhen9,Heenan Laura9,Masjuan Jaime10ORCID,Christensen Hanne11ORCID,Connolly Stuart J.12ORCID,Khatri Pooja13ORCID,Mundl Hardi14ORCID,Hart Robert G.3ORCID,Smith Eric E.1

Affiliation:

1. Department of Clinical Neurosciences, University of Calgary, Canada (C.-H.C., F.S., E.E.S.).

2. Department of Neurology, National Taiwan University Hospital, Taipei (C.-H.C.).

3. Department of Medicine (Neurology) (A.S., R.G.H.), Population Health Research Institute, McMaster University, Hamilton, Canada.

4. Bayer U.S. Pharmaceuticals, Whippany, NJ (P.C.).

5. Department of Neurology, University Hospitals Leuven, Belgium (R.L.).

6. Department of Neurology and Stroke Center, University Hospital of Basel and University of Basel, Switzerland (G.M.D.M.).

7. Neurology Department and Stroke Center, Kantonsspital St. Gallen, Switzerland (G.M.D.M.).

8. Stroke Unit, Santa Maria della Misericordia Hospital, University of Perugia, Italy (V.C.).

9. Department of Statistics, Population Health Research Institute, McMaster University, Hamilton, Canada (L.X., L.H.).

10. Neurology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain (J.M.).

11. Department of Neurology, University Hospital of Copenhagen, Bispebjerg, Denmark (H.C.).

12. Department of Medicine (S.J.C.), Population Health Research Institute, McMaster University, Hamilton, Canada.

13. Department of Neurology and Rehabilitation Sciences, University of Cincinnati, OH (P.K.).

14. Bayer AG, TA Thrombosis and Vascular Medicine, Wuppertal, Germany (H.M.).

Abstract

BACKGROUND: In the phase 2 PACIFIC-STROKE trial (Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following Acute Noncardioembolic Stroke), asundexian, an oral factor XIa inhibitor, did not increase the risk of hemorrhagic transformation (HT). In this secondary analysis, we aimed to investigate the frequency, types, and risk factors of HT on brain magnetic resonance imaging (MRI). METHODS: This was a secondary analysis of the PACIFIC-STROKE trial. Patients with mild-to-moderate acute noncardioembolic ischemic stroke were randomly assigned to asundexian or placebo plus guideline-based antiplatelet therapy. Brain MRIs were required at baseline (≤120 hours after stroke onset) and at 26 weeks or end-of-study. HT was defined using the Heidelberg classification and classified as early HT (identified on baseline MRI) or late HT (new HT by 26 weeks) based on iron-sensitive sequences. Multivariable logistic regression models were used to test factors that are associated with early HT and late HT, respectively. RESULTS: Of 1745 patients with adequate baseline brain MRI (mean age, 67 years; mean National Institutes of Health Stroke Scale score, 2.8), early HT at baseline was detected in 497 (28.4%). Most were hemorrhagic infarctions (hemorrhagic infarction type 1: 15.2%; HI2: 12.7%) while a few were parenchymal hematomas (parenchymal hematoma type 1: 0.4%; parenchymal hematoma type 2: 0.2%). Early HT was more frequent with longer symptom onset-to-MRI interval. Male sex, diabetes, higher National Institutes of Health Stroke Scale large (>15 mm) infarct size, cortical involvement by infarct, higher number of acute infarcts, presence of chronic brain infarct, cerebral microbleed, and chronic cortical superficial siderosis were independently associated with early HT in the multivariable logistic regression model. Of 1507 with follow-up MRI, HT was seen in 642 (42.6%) overall, including 361 patients (23.9%) with late HT (new HT: 306; increased grade of baseline HT: 55). Higher National Institutes of Health Stroke Scale, large infarct size, cortical involvement of infarct, and higher number of acute infarcts predicted late HT. CONCLUSIONS: About 28% of patients with noncardioembolic stroke had early HT, and 24% had late HT detectable by MRI. Given the high frequency of HT on MRI, more research is needed on how it influences treatment decisions and outcomes.

Publisher

Ovid Technologies (Wolters Kluwer Health)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3